ライフサイエンスコーパス: risedronate

1 n various proportions) and a bisphosphonate (risedronate).

2 III: 21 placebo/risedronate, 17 anastrozole/risedronate).

3 res (111 receiving placebo and 195 receiving risedronate).

4 lendronate, 20 with ibandronate, and 14 with risedronate.

5 ceiving teriparatide than in those receiving risedronate.

6 of the bone-resorption drugs zoledronate and risedronate.

7 Bone turnover was reduced with risedronate.

8 essive OA, was seen in patients who received risedronate.

9 resorption therapy, such as pamidronate and risedronate.

10 ing bisphosphonates, such as pamidronate and risedronate.

11 trozole/risedronate; stratum III: 21 placebo/risedronate, 17 anastrozole/risedronate).

12 Patients received either risedronate (2.5 mg or 5 mg) or placebo daily for 12 mon

13 ystem in a 2:1 ratio to receive either daily risedronate (2.5 or 5 mg) or placebo for 1 year.

14 d to receive oral treatment for 3 years with risedronate (2.5 or 5 mg/d) or placebo.

15 omly assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three y

16 ; stratum II: 39 placebo/placebo, 25 placebo/risedronate, 34 anastrozole/placebo, and 34 anastrozole/

17 cancer were randomly assigned to once-weekly risedronate 35 mg or placebo for 24 months.

18 daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these ther

19 st risk (H) received anastrozole 1 mg/d plus risedronate 35 mg/wk orally.

20 n stratum II were randomly assigned (1:1) to risedronate (35 mg/week) or matched placebo by use of a

21 ed only; women in stratum III were all given risedronate (35 mg/week).

22 logues of the anti-resorptive bisphosphonate risedronate (5, Ris) and its phosphonocarboxylate cognat

23 in a double-blind manner to anastrozole and risedronate (A + R) or to anastrozole and placebo (A + P

24 Risedronate, a new pyridinyl bisphosphonate, is a potent

25 Risedronate, a potent bisphosphonate, has been shown to

26 dence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, and alendronate

27 In women on risedronate + AI, the spine decreased by 2.4% +/- 1.1% (

28 urrent treatment with GCs (prednisolone) and risedronate (an aminobisphosphonate) would prevent the r

29 e aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bis

30 ture was 4.2 percent among those assigned to risedronate and 5.1 percent among those assigned to plac

31 ations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of ovarian cancer c

32 xylate analogue of the potent bisphosphonate risedronate and is a weak anti-resorptive agent.

33 nitrogen-containing bisphosphonates (N-BP): risedronate and its analogues 2-(2-aminophenyl)-1-hydrox

34 The mean differences in BMD between the 5-mg risedronate and the placebo groups were 3.8 +/- 0.8% at

35 Myeloma cells or monocytes pulsed with risedronate and then washed rendered these target cells

36 ctures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in

37 ated according with BPs type (alendronate or risedronate) and regimen (daily or weekly), nor with co-

38 osteoporosis (alendronate, ibandronate, and risedronate) and treatment/prevention of skeletal-relate

39 (272 patients on zoledronic acid and 273 on risedronate), and the prevention subgroup of those treat

40 Good evidence suggests that alendronate, risedronate, and estrogen prevent hip fractures more tha

41 avage of Mst1 kinase induced by alendronate, risedronate, and lovastatin, but not clodronate, are blo

42 Soy isoflavones, although not as potent as risedronate, are effective bone-preserving agents in pos

43 D between groups, with a loss of 4.3% in the risedronate arm and 5.4% for placebo at 1 year (P = .18)

44 The 2.5 mg/d of risedronate arm was discontinued after 1 year; in the pl

45 d after 1 year; in the placebo and 5 mg/d of risedronate arms, 450 and 489 subjects, respectively, co

46 was a moderate effect compared with that of risedronate at 15.3% (95% CI: 7.1%, 22.7%; P = 0.0014).

47 These studies evaluated the efficacy of risedronate at dosages of 5 mg/day, 15 mg/day, 35 mg/wee

48 djuvant anastrozole for EBC, the addition of risedronate at doses established for preventing and trea

49 ross-polarization measurements indicate that risedronate binds weakly, since it has a primarily neutr

50 Women who received risedronate but no AI had the greatest improvement in BM

51 endronate, pamidronate, homorisedronate, and risedronate but was less sensitive to the non-nitrogen-c

52 umber of adverse events was demonstrated for risedronate compared with placebo.

53 Although risedronate (compared with placebo) did not improve sign

54 Treatment with 5 mg/d of risedronate, compared with placebo, decreased the cumula

55 Risedronate counterbalances the effect of anastrozole-in

56 acceptable to patients than is 5 mg of oral risedronate daily for prevention and treatment of bone l

57 d in all groups, with no treatment effect of risedronate demonstrated.

58 Risedronate did associate with increased osteoid volume

59 Treatment with risedronate did not affect bone mineral density (BMD) in

60 Risedronate did not prevent bone loss in premenopausal w

61 Risedronate did not significantly reduce radiographic pr

62 re treated with GCs plus placebo or GCs plus risedronate for 1 year.

63 Thereafter, all children received risedronate for 2 additional years in an open-label exte

64 dronic acid was non-inferior and superior to risedronate for increase of lumbar spine bone mineral de

65 ledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocortico

66 infusion of zoledronic acid versus 5 mg oral risedronate for prevention and treatment of glucocortico

67 We assessed effectiveness of oral risedronate for prevention of reduction in bone mineral

68 in 2004, she received oral Bisphosphonates (Risedronate) from 2004 until 2007 followed by two infusi

69 group compared with 61 (9.8%) of 680 in the risedronate group (hazard ratio 0.48, 95% CI 0.32-0.74;

70 the teriparatide group and 38 (6.1%) in the risedronate group (hazard ratio 0.66; 95% CI 0.39-1.10;

71 group and 64 (12.0%) of 680 patients in the risedronate group (risk ratio 0.44, 95% CI 0.29-0.68; p<

72 d occurred in 29 (31%) of 94 patients in the risedronate group and 24 (49%) of 49 patients in the pla

73 7 patients, 97 were randomly assigned to the risedronate group and 50 to the placebo group.

74 pine areal BMD after 1 year was 16.3% in the risedronate group and 7.6% in the placebo group (differe

75 Three patients from the risedronate group and one from the placebo group did not

76 in 9 of 221 (4.1%) evaluable subjects in the risedronate group compared with 30 of 227 (13.2%) in the

77 vertebral fracture was observed in the 5-mg risedronate group compared with the placebo group (5.7%

78 Mean gastric endoscopy scores for the risedronate group were lower than those for the alendron

79 alendronate group, compared with none in the risedronate group, and duodenal ulcers were noted in 1 e

80 ubject in the alendronate group and 2 in the risedronate group.

81 (0.6 +/- 0.5%) or the 2.5-mg (-0.1 +/- 0.7%) risedronate groups, while it decreased in the placebo gr

82 he spine and hip BMD between the placebo and risedronate groups.

83 delta T cells in vitro and in vivo (potency: risedronate > alendronate > pamidronate) requires expres

84 I and II who were not randomly allocated to risedronate had both baseline and 3 year assessments.

85 ferences in fracture risk were found between risedronate (hazard ratio [HR], 1.01 [95% CI, 0.85 to 1.

86 values against parasite replication (e.g. o-risedronate, IC(50) = 220 nM for T. brucei rhodesiense;

87 , IC(50) = 220 nM for T. brucei rhodesiense; risedronate, IC(50) = 490 nM for T. gondii).

88 14 muM), zoledronic acid (IC50 = 21-57 muM), risedronate (IC50 > 100 muM) or GGTI-2133 (IC50 > 25 muM

89 anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.

90 re-modifying OA drug, tested the efficacy of risedronate in providing symptom relief and slowing dise

91 Women not receiving risedronate in stratum I and II who received anastrozole

92 t of the nitrogen-containing bisphosphonate, risedronate, in T. b. rhodesiense is the enzyme farnesyl

93 The overall safety profile of risedronate, including gastrointestinal safety, was simi

94 Oral risedronate increased areal BMD and reduced the risk of

95 Risedronate increases bone mineral density in elderly wo

96 The N-BPs alendronate and risedronate inhibited NHEK growth in a dose-dependent ma

97 Risedronate is a commonly used third-generation amino-bi

98 ruzi, the nitrogen-containing bisphosphonate risedronate is shown to inhibit sterol biosynthesis at a

99 ients given zoledronic acid than in those on risedronate, largely as a result of transient symptoms d

100 postmenopausal women (n = 515) received 5 mg risedronate (n = 255) or 10 mg alendronate (n = 260) for

101 ed 1:1 to receive zoledronic acid (n=416) or risedronate (n=417).

102 e treated with E, CT, or the bisphosphonate, Risedronate (NE).

103 In contrast to risedronate, NE10790 inhibited bone resorption in vitro

104 d pamidronate, alendronate, zoledronate, and risedronate on bone show that all side chains undergo fa

105 ly plus oral weekly placebo or 35 mg of oral risedronate once weekly plus daily injections of placebo

106 o be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity.

107 randomly allocated to anastrozole and either risedronate or placebo had baseline and 3 year assessmen

108 Differences in fracture risk between risedronate or raloxifene and alendronate were small.

109 ed with prednisolone pellets alone, GCs plus risedronate, or placebo alone and iliac crest biopsy spe

110 sts, we examined the effects of alendronate, risedronate, pamidronate, etidronate, and clodronate on

111 In addition, treatment with risedronate plus GCs in mice appeared to preserve bone c

112 Concurrent treatment with GCs and risedronate prevented the deterioration of trabecular bo

113 Risedronate prevented the localized changes in mineral a

114 Risedronate prevents bone loss in postmenopausal women.

115 rpose of this study was to determine whether risedronate prevents bone loss in premenopausal women un

116 Risedronate should be regarded as a treatment option for

117 Risedronate significantly reduces the risk of hip fractu

118 f 87 patients in the group that had received risedronate since the start of the study, and 32 (65%) o

119 ole (1 mg/day) on BMD in women not receiving risedronate (strata I and II) and in osteoporotic women

120 osteoporotic women who were all treated with risedronate (stratum III).

121 , 34 anastrozole/placebo, and 34 anastrozole/risedronate; stratum III: 21 placebo/risedronate, 17 ana

122 mines the safety and efficacy of daily, oral risedronate therapy for the prevention of corticosteroid

123 These data suggest that risedronate therapy is effective and well tolerated in t

124 Risedronate therapy prevents bone loss in patients initi

125 For alendronate and risedronate, these events seem to be downstream of inhib

126 Bone formed during risedronate treatment was histologically normal.

127 l trials (prevention and treatment trials of risedronate) using similar methods, but different inclus

128 and 3 year DXA assessment) was the effect of risedronate versus placebo for osteopenic women in strat

129 n BMD change for women receiving anastrozole/risedronate was -0.7% (-1.6 to 0.2) versus -3.5% (-4.6 t

130 hange for the 77 women receiving anastrozole/risedronate was 1.1% (95% CI 0.2 to 2.1) versus -2.6% (-

131 ence of hip fracture among those assigned to risedronate was 1.9 percent, as compared with 3.2 percen

132 hip fracture among all the women assigned to risedronate was 2.8 percent, as compared with 3.9 percen

133 Risedronate was active in vivo against T. brucei infecti

134 oses used for the treatment of osteoporosis, risedronate was associated with a significantly lower in

135 with or without AI therapy, once-weekly oral risedronate was beneficial for spine and hip BMD, reduce

136 Risedronate was well tolerated, and the incidence of upp

137 Risedronate was well tolerated, with no significant diff

138 g-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months.

139 ios (RORs) for alendronate, ibandronate, and risedronate were 3.82 (95% CI: 2.94-4.96), 2.40 (95% CI:

140 Safety profiles for anastrozole and risedronate were similar to those already established.

141 s that alendronate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, parathyroid horm

142 er pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the